Lung | Interview with Jamie E Chaft, MD

1:11:32
 
Share
 

Manage episode 229586041 series 1464352
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Lung Cancer Update – Part 2: Our interview with Dr Chaft highlights the following topics as well as cases from her practice:

  • Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion: 0m0s
  • Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC: 3m2s
  • Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors: 6m41s
  • Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies: 7m52s
  • Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation: 12m10s
  • Risks and benefits with osimertinib in the adjuvant setting: 14m38s
  • Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer: 17m31s
  • Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation: 19m5s
  • Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy: 22m58s
  • Management of superior vena cava syndrome in patients with lung cancer: 25m23s
  • Activity and tolerability of durvalumab as consolidation therapy: 27m50s
  • Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC: 29m15s
  • Recognition and management of pneumonitis associated with durvalumab/radiation therapy: 30m53s
  • Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC: 35m7s
  • Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors: 36m54s
  • Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC: 40m11s
  • Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors: 42m45s
  • Management of metastatic nonsquamous NSCLC in the first-line setting: 46m0s
  • Perspective on the results of the Phase III IMpower150 study: 49m47s
  • Selection of first-line therapy for patients with metastatic squamous NSCLC: 53m3s
  • Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC: 54m44s
  • Therapeutic approach for patients with metastatic small cell lung cancer: 58m18s
  • Duration of therapy with immune checkpoint inhibitors: 1h0m23s
  • Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors: 1h2m18s
  • Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib: 1h4m40s
  • Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib: 1h7m21s

Select publications

2168 episodes available. A new episode about every 0 hours averaging 70 mins duration .